Inflect Expands Strategic Partnership with GEn1E and Invests More!

By Andrew Smith

Today we’re very proud to formally announce that Inflect has expanded our strategic partnership with GEn1E Lifesciences, a multitarget clinical-phase techbio company developing novel, next-generation, and immunomodulatory therapies for rare and inflammatory diseases. Along with this expanded partnership, we are also excited to announce that we have increased our seed investment!

GEn1E leverages multiple-mechanism-of-action protein targets and their natural platform-like capabilities using machine learning. Their platform enhances their decision-making throughout the end-to-end drug development process.

GEn1E was co-founded by Dr. Ritu Lal, a drug development veteran with 20+ years of experience, who set out to address the striking lack of treatments for rare and inflammatory diseases. Since then GEn1E has made unprecedented progress. The company has developed a rich pipeline of 21+ novel immunomodulators using the platform.

Dr. Lal highlights that GEn1E’s platform today is a significant innovation compared to the 1st generation inhibitors, citing that their next-generation compounds are immunomodulatory in stark contrast to previous generation, which were non-selective and immunosuppressive.

Their lead compound is a novel, purpose built therapy for acute respiratory distress syndrome (ARDS), a devastating disease with a high mortality rate (it is the leading cause of death among serious COVID-19 patients) and no approved therapy.

At Inflect, our rich knowledge of healthcare economics across diverse patient populations ensures that GEn1E can identify key areas of high unmet medical need. The team at GEn1E is multi-lingual which means they combine computational methods with biological experiments, and ‘omics data, among other proprietary information to drive their decision-making. This enables them to discover and develop promising drugs much faster than traditional practices.

“We are very grateful for our strategic partners at Inflect Health. Their expertise on the needs of hospital systems and payers, current standard of care, along with key healthcare metrics such as length of stay and readmission rates, are invaluable to the development of new and much-needed therapies faster, better, and more cost-effectively,” said Dr. Ritu Lal.

Visit GEn1E’s homepage here. We are excited to be a part of the GEn1E team’s journey, and can’t wait to share more about its upcoming breakthroughs that will benefit the entire healthcare ecosystem.